Isavuconazole Causes Fewer Side Effects Compared With Voriconazole: ICAAC 2014
Important drug development work carried out by the University of Wurzburg and Johns Hopkins School of Medicine in the US was reported at the recent antimicrobial conference ICAAC 2014.
It had already been established that the new antifungal drug isavuconazole shows much promise for the treatment of aspergillosis. It is at least as good as existing antifungal drugs e.g. voriconazole when
0 Response to "Isavuconazole Causes Fewer Side Effects Compared With Voriconazole: ICAAC 2014"
Post a Comment